Stayble Therapeutics AB (OSTO:STABL) 1-Year Share Buyback Ratio : -37.80% (As of Dec. 2024 )

View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Stayble Therapeutics AB's current 1-Year Share Buyback Ratio was -37.80%.

OSTO:STABL's 1-Year Share Buyback Ratio is ranked worse than
73.17% of 1200 companies
in the Biotechnology industry
Industry Median: -13.65 vs OSTO:STABL: -37.80

Competitive Comparison of Stayble Therapeutics AB's 1-Year Share Buyback Ratio

For the Biotechnology subindustry, Stayble Therapeutics AB's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB's 1-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Stayble Therapeutics AB 1-Year Share Buyback Ratio Calculation

Stayble Therapeutics AB's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(31.721	-	43.721)	/	31.721
	=	-37.8%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stayble Therapeutics AB (OSTO:STABL) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Stayble Therapeutics AB 1-Year Share Buyback Ratio Related Terms

Stayble Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lennart Torstenssonsgatan 6, Gothenburg, SWE, 412 56

Website

https://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB Headlines

No Headlines